Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00616109

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

Extensive-Stage Small Cell Lung Cancer Clinical Trial

Official title:
Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Clinical Trial Summary

The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous platinum chemotherapy regimen, such as cisplatin or carboplatin in combination with etoposide or irinotecan. In addition, the safety and effectiveness of sunitinib will also be evaluated.

Clinical Trial Description

Despite a high initial response rate, all patients with extensive-stage small cell lung cancer treated with standard chemotherapy will develop disease progression, usually within one year of initial treatment. Therefore, prolonging progression-free survival in this disease is meaningful for clinical trials exploring agents such as sunitinib. Sunitinib is a drug that inhibits the biological pathway responsible for the growth and spread of cancer cells. For this reason, we believe that sunitinib maintenance therapy will delay or prevent recurrence and prolong survival.

The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous platinum chemotherapy regimen, such as cisplatin or carboplatin in combination with etoposide or irinotecan. In addition, the safety and effectiveness of sunitinib will also be evaluated. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00616109
Study type Interventional
Source University of Michigan Cancer Center
Contact
Status Completed
Phase Phase 2
Start date September 2007
Completion date January 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05509699 - Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05975944 - Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT04562337 - A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04373369 - Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04254471 - This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients Phase 2/Phase 3
Active, not recruiting NCT04774380 - Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Phase 3
Active, not recruiting NCT01555710 - Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Phase 3
Completed NCT00682981 - A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase 1/Phase 2
Recruiting NCT04397003 - Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04702880 - A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04487756 - Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer Phase 1/Phase 2
Recruiting NCT03135977 - Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy Phase 2
Completed NCT03913455 - Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04663438 - Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
Not yet recruiting NCT03971214 - PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT04101357 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Phase 1/Phase 2
Completed NCT04636762 - A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) Phase 2
Not yet recruiting NCT04404543 - A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer Phase 1
Completed NCT02323737 - Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer Phase 2
Completed NCT03911219 - Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy